Karyopharm Therapeutics Inc. (KPTI) Receives New Coverage from Analysts at Royal Bank Of Canada
Royal Bank Of Canada initiated coverage on shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in a report issued on Thursday morning. The brokerage issued an outperform rating and a $14.00 price target on the stock.
KPTI has been the topic of several other research reports. BidaskClub cut shares of Karyopharm Therapeutics from a sell rating to a strong sell rating in a research note on Monday, July 31st. ValuEngine cut shares of Karyopharm Therapeutics from a hold rating to a sell rating in a report on Thursday, August 31st. Zacks Investment Research upgraded shares of Karyopharm Therapeutics from a hold rating to a buy rating and set a $11.00 target price for the company in a report on Thursday, July 6th. Cantor Fitzgerald set a $18.00 target price on shares of Karyopharm Therapeutics and gave the stock a buy rating in a report on Saturday, June 24th. Finally, Robert W. Baird reiterated an outperform rating and issued a $15.00 target price on shares of Karyopharm Therapeutics in a report on Tuesday, July 4th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. Karyopharm Therapeutics has a consensus rating of Buy and a consensus target price of $15.67.
Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded up 4.07% during trading on Thursday, hitting $11.00. 432,710 shares of the company traded hands. The stock’s market cap is $518.52 million. The firm has a 50 day moving average price of $9.22 and a 200-day moving average price of $9.87. Karyopharm Therapeutics has a one year low of $6.27 and a one year high of $14.63.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.64). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. Karyopharm Therapeutics’s quarterly revenue was down 95.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.84) EPS. Analysts predict that Karyopharm Therapeutics will post ($2.68) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was first published by Daily Political and is owned by of Daily Political. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.dailypolitical.com/2017/09/15/karyopharm-therapeutics-inc-kpti-receives-new-coverage-from-analysts-at-royal-bank-of-canada.html.
Several hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its holdings in shares of Karyopharm Therapeutics by 0.7% during the first quarter. Bank of America Corp DE now owns 46,127 shares of the company’s stock worth $592,000 after purchasing an additional 308 shares during the period. ProShare Advisors LLC boosted its holdings in shares of Karyopharm Therapeutics by 8.0% during the second quarter. ProShare Advisors LLC now owns 27,154 shares of the company’s stock worth $246,000 after purchasing an additional 2,021 shares during the period. American International Group Inc. boosted its holdings in shares of Karyopharm Therapeutics by 20.9% during the first quarter. American International Group Inc. now owns 16,422 shares of the company’s stock worth $211,000 after purchasing an additional 2,836 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in shares of Karyopharm Therapeutics by 4.5% during the first quarter. Schwab Charles Investment Management Inc. now owns 86,514 shares of the company’s stock worth $1,111,000 after purchasing an additional 3,762 shares during the period. Finally, Swiss National Bank boosted its holdings in shares of Karyopharm Therapeutics by 10.9% during the first quarter. Swiss National Bank now owns 40,850 shares of the company’s stock worth $525,000 after purchasing an additional 4,000 shares during the period. Institutional investors and hedge funds own 58.97% of the company’s stock.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.